« WP Backs Genetic Discrimination Bill | Main | Gene Therapy Trial Shows Promise »
April 27, 2004
Amarin Buys An Opinion
Amarin paid a company $25,000 to provide an investment opinion.
No, that isn't that unusual. The investment opinion comes from J.M. Dutton & Associates and this press release seems reasonably accurate. They consider Amarin to be a "Speculative Buy" which is Wall Street talk for "a gamble". This gave the stock a nice little "goose" as it had been trading slightly about the dreaded $1/share mark. The price declined in late trading but it was still up 6% for the day.
For those who don't know...Amarin has LAX-101 (a Huntington's Disease drug) entering a second round of Phase III drug trials. Here's the press release for your enjoyment.
Posted by Dave at April 27, 2004 08:37 PM
Trackback Pings
TrackBack URL for this entry:
http://www.huntingtons.info/MT/mt-tb.cgi/417
Comments
Post a comment
Thanks for signing in, . Now you can comment. (sign out)
(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)